Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Susan Darlow
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Susan Darlow wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 2017

Tempero, Margaret A / Malafa, Mokenge P / Al-Hawary, Mahmoud / Asbun, Horacio / Bain, Andrew / Behrman, Stephen W / Benson, Al B / Binder, Ellen / Cardin, Dana B / Cha, Charles / Chiorean, E Gabriela / Chung, Vincent / Czito, Brian / Dillhoff, Mary / Dotan, Efrat / Ferrone, Cristina R / Hardacre, Jeffrey / Hawkins, William G / Herman, Joseph / Ko, Andrew H / Komanduri, Srinadh / Koong, Albert / LoConte, Noelle / Lowy, Andrew M / Moravek, Cassadie / Nakakura, Eric K / O'Reilly, Eileen M / Obando, Jorge / Reddy, Sushanth / Scaife, Courtney / Thayer, Sarah / Weekes, Colin D / Wolff, Robert A / Wolpin, Brian M / Burns, Jennifer / Darlow, Susan. · ·J Natl Compr Canc Netw · Pubmed #28784865.

ABSTRACT: Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

2 Article Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. 2016

Daly, Mary B / Pilarski, Robert / Axilbund, Jennifer E / Berry, Michael / Buys, Saundra S / Crawford, Beth / Farmer, Meagan / Friedman, Susan / Garber, Judy E / Khan, Seema / Klein, Catherine / Kohlmann, Wendy / Kurian, Allison / Litton, Jennifer K / Madlensky, Lisa / Marcom, P Kelly / Merajver, Sofia D / Offit, Kenneth / Pal, Tuya / Rana, Huma / Reiser, Gwen / Robson, Mark E / Shannon, Kristen Mahoney / Swisher, Elizabeth / Voian, Nicoleta C / Weitzel, Jeffrey N / Whelan, Alison / Wick, Myra J / Wiesner, Georgia L / Dwyer, Mary / Kumar, Rashmi / Darlow, Susan. ·Fox Chase Cancer Center · The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute · The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center · Huntsman Cancer Institute at the University of Utah · UCSF Helen Diller Family Comprehensive Cancer Center · University of Alabama at Birmingham Comprehensive Cancer Center · FORCE-Facing Our Risk of Cancer Empowered · Dana-Farber/Brigham and Women’s Cancer Center · Robert H. Lurie Comprehensive Cancer Center of Northwestern University · University of Colorado Cancer Center · Stanford Cancer Institute · The University of Texas MD Anderson Cancer Center · UC San Diego Moores Cancer Center · Duke Cancer Institute · University of Michigan Comprehensive Cancer Center · Memorial Sloan Kettering Cancer Center · Moffitt Cancer Center · Fred & Pamela Buffett Cancer Center · Massachusetts General Hospital Cancer Center · University of Washington Medical Center/Seattle Cancer Care Alliance · Roswell Park Cancer Institute · City of Hope Comprehensive Cancer Center · Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine · Mayo Clinic Cancer Center · Vanderbilt-Ingram Cancer Center · National Comprehensive Cancer Network ·J Natl Compr Canc Netw · Pubmed #26850485.

ABSTRACT: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.